- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
|Compound class||Endogenous peptide in human, mouse or rat|
|IL-33 is an IL-1 family cytokine. Its main cellular targets are innate lymphoid cells type 2 (ILC2), involved in the initiation of the type 2 immune response (secretion of IL-5 and IL-13) during parasitic infection and allergic diseases such as asthma. Full length IL-33 is cleaved by mast cell chymase (chymase 1; CMA1) to produce its significantly more active form .
The ST2/IL-33 axis is recognized as playing an important role in the development/exacerbation of IgE-dependent inflammations such as asthma and atopic dermatitis [1,3], and is therefore receiving much interest from the pharmaceutical industry. Blockade of IL-33 activity (and/or its receptor ST2) represent potential novel mechanisms for pharmaceutical intervention to suppress allergy and mast cell-eosinophil interplay. Indeed, mAb AMG 282 (RG6149) is an example of a fully human anti-IL-33 monoclonal antibody, that is in Phase 1 development as a potential therapy for mild atopic asthma and chronic rhinosinusitis.
|Ensembl Gene||ENSG00000137033 (Hs)|
|GtoPdb PubChem SID||178102504|
|Human Protein Atlas||ENSG00000137033 (Hs)|